Veritas In Silico Inc.

130A

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-05FY2026 Q2

Revenue

YoY -

Operating Income

-2.5100M JPY

YoY -32.3%

Net Income

-6.3100M JPY

YoY -89.8%

EPS

-59.6JPY

YoY -109.6%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

3.6億円

1.6億円

-32.8百万円

-2.3億円

-4.3億円

Rev: 3.6億円Op: 37.6百万円NI: 33百万円

Rev: -Op: -2.1億円NI: -2.4億円

Rev: -Op: -4億円NI: -4.3億円

2023/FY2024/FY2025/FY

Full-Year Progress

FY2026 Q2

Net Income-

Revenue Progress-

Revenue Forecast-

Net Income Progress-

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan